HCW Biologics Inc. HCWB
1.93
(0.06)
(3.02%)
as of 25 Sep
- Market cap
- $4.2M
- P/E
- 0.0×
Follow HCWB
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
367.75% | 1,113.43% | 1,346.29% | (600.32%) | |
| (85.40%) | (81.45%) | (70.29%) | (79.52%) | ||
ROIC |
(205.79%) | (107.94%) | (44.78%) | (36.15%) | |
Return on Tangible Assets |
801.83% | (1,060.53%) | (745.32%) | (683.79%) | |
Average Days of Receivables |
26.55 | 216.45 | 4.14 | 1.00 | |
Free Cash Flow per Share |
(34.17) | (38.29) | (12.67) | (9.14) | |
Free Cash Flow |
(12.87) | (13.39) | (11.45) | (12.14) | |
Piotroski F-Score |
3.00 | 3.00 | 6.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(222.02%) | (116.18%) | (84.41%) | (82.39%) | |
Accounts Receivable Turnover |
1.24 | 0.18 | 81.23 | 335.22 | |
Accounts Payable Turnover |
0.02 | 0.00 | 0.00 | 0.02 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
20,507.68 | 110,537.81 | 85,354.96 | 14,097.74 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,222.29% | 10,023.57% | 79.21% | 77.35% | |
Selling, General and Administrative Expense of Revenue |
1,950.08% | 14,182.87% | 110.84% | 105.36% | |
Share Based Compensation of Revenue |
249.11% | 1,415.47% | 7.63% | 3.36% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.58 | 0.60 | 0.61 | 0.55 | |
Depreciation/Fixed assets |
0.07 | 0.05 | 0.04 | 0.03 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
1.12 | 0.16 | 7.29 | 5.06 | |
Operating CF per Share |
(34.17) | (38.29) | (12.67) | (9.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(5,260.84%) | (41,065.75%) | (285.88%) | (329.38%) |
Columns are period end dates